Loading...
XHKG1696
Market cap215mUSD
Dec 23, Last price  
3.58HKD
1D
-1.10%
1Q
4.68%
IPO
-59.78%
Name

Sisram Medical Ltd

Chart & Performance

D1W1MN
XHKG:1696 chart
P/E
6.85
P/S
0.60
EPS
0.07
Div Yield, %
0.63%
Shrs. gr., 5y
1.16%
Rev. gr., 5y
18.48%
Revenues
359m
+1.36%
101,321,000110,406,000118,156,000136,887,000153,919,000173,520,000162,095,000294,294,000354,480,000359,292,000
Net income
31m
-21.59%
5,943,0007,814,0008,055,00011,049,00021,831,00020,785,00013,344,00031,245,00040,170,00031,499,000
CFO
44m
+99.36%
22,807,00015,847,00016,013,00017,057,00016,236,00021,037,00025,737,00032,377,00022,039,00043,936,000
Dividend
Aug 26, 20240.158 HKD/sh

Profile

Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical, minimally invasive treatment systems, and non-energy based devices and cosmeceuticals in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. It offers products and treatments portfolio, including hair removal, skin rejuvenation, acne and acne scars, body and face contouring, pigmentation and skin resurfacing, fat grafting, dermal facial fillers, skin tissue remodelling injectables, personal care, aesthetic dentistry, trans epidermal delivery, cellulite treatment, stretch marks, vascular and pigmented lesions, hydradermabrasion, blepharoplasty-non surgical eyelid lift, liposuction, feminine health, and sexual rehabilitation. The company manufactures, distributes, and sells medical equipment. It offers its products under the Alma, Soprano, Harmony, Copulla, Foshion, Accent, and LMNT brands. Sisram Medical Ltd was incorporated in 2013 and is headquartered in Caesarea, Israel.
URL
https://sisram-medical.com/
IPO date
Sep 19, 2017
Employees
1,102
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
359,292
1.36%
354,480
20.45%
294,294
81.56%
Cost of revenue
317,233
299,036
243,735
Unusual Expense (Income)
NOPBT
42,059
55,444
50,559
NOPBT Margin
11.71%
15.64%
17.18%
Operating Taxes
4,232
4,162
9,152
Tax Rate
10.06%
7.51%
18.10%
NOPAT
37,827
51,282
41,407
Net income
31,499
-21.59%
40,170
28.56%
31,245
134.15%
Dividends
(10,510)
(9,325)
(4,191)
Dividend yield
0.43%
0.22%
0.10%
Proceeds from repurchase of equity
76,898
BB yield
-1.79%
Debt
Debt current
9,138
8,623
10,386
Long-term debt
75,805
68,316
65,563
Deferred revenue
592
262
Other long-term liabilities
20,183
1,295
2,045
Net debt
8,186
(20,881)
(84,144)
Cash flow
Cash from operating activities
43,936
22,039
32,377
CAPEX
(8,568)
(64,323)
(2,965)
Cash from investing activities
(32,995)
(52,113)
(46,767)
Cash from financing activities
(20,966)
(17,847)
55,777
FCF
993
23,434
11,255
Balance
Cash
70,601
81,414
152,920
Long term investments
6,156
16,406
7,173
Excess cash
58,792
80,096
145,378
Stockholders' equity
174,878
138,312
107,016
Invested Capital
475,598
392,427
335,676
ROIC
8.72%
14.09%
13.47%
ROCE
7.87%
11.52%
11.18%
EV
Common stock shares outstanding
468,343
466,774
452,868
Price
5.26
-41.03%
8.92
-6.01%
9.49
184.13%
Market cap
2,463,485
-40.83%
4,163,627
-3.12%
4,297,714
191.02%
EV
2,488,885
4,171,718
4,238,273
EBITDA
56,294
67,846
62,844
EV/EBITDA
44.21
61.49
67.44
Interest
2,064
1,972
2,005
Interest/NOPBT
4.91%
3.56%
3.97%